Document is current
Any future updates will be listed below
-
Authors
Wang, Chen https://orcid.org/0000-0003-2271-5587
Barnoud, Coline https://orcid.org/0000-0001-5500-0217
Cenerenti, Mara
Sun, Mengzhu
Caffa, Irene
Kizil, Burak https://orcid.org/0000-0003-2348-1305
Bill, Ruben
Liu, Yuanlong
Pick, Robert https://orcid.org/0000-0001-9785-8481
Garnier, Laure
Gkountidi, Olga A.
Ince, Louise M. https://orcid.org/0000-0002-2093-0876
Holtkamp, Stephan
Fournier, Nadine https://orcid.org/0000-0002-9347-7929
Michielin, Olivier
Speiser, Daniel E.
Hugues, Stéphanie
Nencioni, Alessio https://orcid.org/0000-0001-5068-8884
Pittet, Mikaël J. https://orcid.org/0000-0002-2060-4691
Jandus, Camilla https://orcid.org/0000-0002-7405-5747
Scheiermann, Christoph https://orcid.org/0000-0002-9212-0995
- License Information
-
More Information
Article History
Received: 14 April 2022
Accepted: 25 November 2022
First Online: 5 December 2022
Competing interests
: M.J.P. has been a consultant for AstraZeneca, Debiopharm, Elstar Therapeutics, ImmuneOncia, KSQ Therapeutics, MaxiVax, Merck, Molecular Partners, Third Rock Ventures and Tidal; these relationships are unrelated to the current study. The other authors declare no competing interests.
